News – Page 903 – Endpoints News

Amgen commits to low-cost Repatha; AZTherapies bags Smith Therapeutics' CAR-Treg tech for neuroinflammation

6 years ago

Syros pushes for a turnaround with new PhII AML results, but investors are unimpressed

6 years ago

Impressing analysts with a big Q3, AstraZeneca whisks away the losers in the pipeline

6 years ago

Vertex finally makes NICE with England's NHS on CF therapies, but runs into hiccup with preclinical kidney drug data

6 years ago

Public funds help late-stage development of about 25% of new drugs, study finds

6 years ago

From $0 to $12B in an instant. Here's why biopharma loves risky Alzheimer's studies

6 years ago

Allievex launches with Pappas cash and rare disease drug from BioMarin

6 years ago

As clock ticks, Trump will nominate Stephen Hahn as FDA commissioner next week — report

6 years ago

Go big or go home: NIH, Bill and Melinda Gates Foundation join forces to make gene therapies affordable

6 years ago

GlaxoSmithKline celebrates another Zejula win in late-line ovarian cancer — and an FDA nod for the HRD biomarker

6 years ago

Acorda's Ron Cohen brings the ax back out as new drug sales only trickle in while cash cow is led to the slaughter

6 years ago

NeuroRx secures $95M to fund PhIII for NMDA depression drug; Trump revives science advisory council

6 years ago

RAPT Therapeutics returns to Wall Street to revive IPO bid

6 years ago

EY vet set to replace retiring Amgen CFO Meline

6 years ago

As shares suffer from a lingering slump, a bruised Alkermes slashes 160 jobs in R&D restructuring

6 years ago

Jean-Paul Clozel downplays recruitment delays holding up PhIII for Fabry disease

6 years ago

Eli Lilly’s USA, diabetes chief Enrique Conterno is heading out after 27 years, and he’s being replaced by a ...

6 years ago

Zealand takes on Takeda's IBD drug with tiny buyout

6 years ago

Novartis hands off $80M in cash to partner up with a top biotech player in the fibrosis sector

6 years ago

Is there a recipe for M&A success? The best and worst buyout deals in the past decade offer some keys to success — ...

6 years ago

Soriot, Schleifer, Perreault named top global CEOs — but gone are pharma's golden years

6 years ago

Provention Bio's J&J-licensed Crohn's drug stumbles in mid-stage study

6 years ago

David Liu unveils newest advancement in CRISPR tech: Prime editing

6 years ago

CD47 player Trillium chops discovery efforts and 40% of staff; Brii Bio inks deal to bring antibiotics to China

6 years ago

First page Previous page 900 901 902903904 905 906 Next page Last page